Merck’s COVID Pill Loses Its Lustre: What That Means for the Pandemic

Molnupiravir, one of two antiviral pills that have caused excitement in the past few months because preliminary clinical-trial results showed that they can significantly reduce hospitalizations and deaths from COVID-19, has yet to receive an emergency use authorization from the US FDA.